Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RGLS

RGLS - Regulus Therapeutics Inc Stock Price, Fair Value and News

$8.16 
Market Closed

Price Targets

RGLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGLS Price Action

Last 7 days

-2.8%

Last 30 days

-0.5%

Last 90 days

475.2%

Trailing 12 Months

212.7%

RGLS RSI Chart

RGLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGLS Valuation

Market Cap

565.0M

Price/Earnings (Trailing)

-11.89

Price/Sales (Trailing)

130.64

EV/EBITDA

-10.93

Price/Free Cashflow

-12.94

RGLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

RGLS Fundamentals

RGLS Revenue

Revenue (TTM)

4.3M

RGLS Earnings

Earnings (TTM)

-47.5M

RGLS Profitability

EBT Margin

-1098.90%

Return on Equity

-68.85%

Return on Assets

-63.51%

Free Cashflow Yield

-7.73%

RGLS Investor Care

Shares Dilution (1Y)

5.76%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.7M2.5M3.2M3.8M
2023976.0K1.4M1.7M1.7M
2022001.1M562.0K
2021010.4M10.8M5.9M
20207.6M8.4M9.2M10.0M
20192.8M4.1M5.5M6.8M
201872.0K72.0K72.0K1.4M
2017913.5K633.0K352.5K72.0K
201615.9M11.0M6.1M1.2M
201510.2M13.3M14.1M20.8M
201418.0M13.9M8.9M7.7M
201312.6M14.0M17.4M19.6M
201213.8M13.8M12.8M12.7M
20119.9M11.2M12.5M13.8M
20100008.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Regulus Therapeutics Inc

RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
 CEO
 WEBSITEregulusrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30

Regulus Therapeutics Inc Frequently Asked Questions

RGLS is the stock ticker symbol of Regulus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jun 26 2025, market cap of Regulus Therapeutics Inc is 564.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RGLS's fair value in chart for subscribers.

The fair value guage provides a quick view whether RGLS is over valued or under valued. Whether Regulus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Regulus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGLS.

As of Thu Jun 26 2025, RGLS's PE ratio (Price to Earnings) is -11.89 and Price to Sales (PS) ratio is 130.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGLS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Regulus Therapeutics Inc has provided -0.399 (multiply by 100 for percentage) rate of return.